Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
View AllImproved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- GB
- Publications
- 4
- Citations
- 8,344
External Links
Identifiers
- ROR
- https://ror.org/03v9efr22